Medivir to present at the Pareto Securities Healthcare ConferenceRead more
Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical studyRead more
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCARead more
Quarterly report presentations
Medivir Corporate Governance documention.
Documentation from Medivir's Annual General Meetings.